<p>Kayfanda is a medicine used for treating cholestatic pruritus (intense itching due to a build-up of bile) caused by Alagille syndrome in patients aged 6 months and older.</p><p>Alagille syndrome is an inherited disease in which bile (a fluid produced in the liver that helps to break down fats) cannot drain properly from the liver, resulting in a build-up of bile acid in the liver and blood. One of the symptoms of this build-up is cholestatic pruritus.</p><p>Kayfanda contains the active substance odevixibat. </p><p> </p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1).</p></div>
Therapeutic Area (MeSH)
ATC Code
A05AX05
ATC Item
N/A
Pharmacotherapeutic Group
Bile and liver therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| odevixibat sesquihydrate | N/A | odevixibat sesquihydrate |
EMA Name
Kayfanda
Medicine Name
Kayfanda
Aliases
N/ANo risk management plan link.
